Use of Niacin for Primary or Secondary Prevention of Cardiovascular or Cerebrovascular Events

. 2018 Apr 1;97(7):436-437.

Affiliations

Free article

Joseph R Yancey et al. Am Fam Physician. 2018.

Free article

. 2018 Apr 1;97(7):436-437.

No abstract available

Comment in

Does Niacin Have Cardiovascular Benefits in Patients with Dyslipidemia?
Wojcik C. Wojcik C. Am Fam Physician. 2018 Dec 1;98(11):631-632. Am Fam Physician. 2018. PMID: 30485054 No abstract available.

Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
Verdoia M, Schaffer A, Suryapranata H, De Luca G. Verdoia M, et al. Nutr Metab Cardiovasc Dis. 2015 Jan;25(1):9-23. doi: 10.1016/j.numecd.2014.09.003. Epub 2014 Sep 28. Nutr Metab Cardiovasc Dis. 2015. PMID: 25439661
Effect of niacin on atherosclerotic cardiovascular disease.
Guyton JR. Guyton JR. Am J Cardiol. 1998 Dec 17;82(12A):18U-23U; discussion 39U-41U. doi: 10.1016/s0002-9149(98)00767-x. Am J Cardiol. 1998. PMID: 9915658 Review.
Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis.
de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. de Vries FM, et al. PLoS One. 2014 Nov 5;9(11):e111247. doi: 10.1371/journal.pone.0111247. eCollection 2014. PLoS One. 2014. PMID: 25372483 Free PMC article.
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ, Watson KE, Talbert RL. Cziraky MJ, et al. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review.
Nonstatin therapies for management of dyslipidemia: a review.
Sando KR, Knight M. Sando KR, et al. Clin Ther. 2015 Oct 1;37(10):2153-79. doi: 10.1016/j.clinthera.2015.09.001. Epub 2015 Sep 26. Clin Ther. 2015. PMID: 26412799 Review.